US 9474780

US Patent 9474780: GIP and GLP-1 Co-Agonist Compounds

Title: GIP and GLP-1 co-agonist compounds
Assignee: Eli Lilly and Co
Inventors: Bengt Krister Bokvist, Tamer Coskun, Robert Chadwick Cummins, Jorge Alsina-Fernandez
Filing Date: January 5, 2016
Issue Date: October 25, 2016
Abstract: The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These compounds may be useful for treating type 2 diabetes mellitus (T2D).

---

Plain-Language Overview of Independent Claims:

Independent Claim 1:
This claim describes a specific chemical compound, a peptide, designed to act as a dual agonist for GIP and GLP-1 receptors. The peptide has a defined sequence (YX1EGTFTSDYSIX2LDKIAQKAX3VQWLIAGGPSSGAPPPS), where X1 and X2 are a non-natural amino acid called Aib (alpha amino isobutyric acid). The lysine (K) at position 20 is chemically modified by attaching a specific linker-fatty acid chain. This chain includes two ([2-(2-Amino-ethoxy)-ethoxy]-acetyl) units, followed by one or two gamma-glutamic acid (γGlu) units, and then a fatty acid chain of 10 to 20 carbon atoms (—CO—(CH2)b—CO2H where b is 10-20). X3 can be either Phenylalanine (Phe) or 1-Naphthylalanine (1-Nal). The very last amino acid of the peptide can optionally be amidated (forming a C-terminal primary amide). The claim also covers pharmaceutically acceptable salts of this compound.

Independent Claim 15:
This claim covers a pharmaceutical composition. It states that this composition comprises the compound described in Claim 1, along with at least one pharmaceutically acceptable carrier, diluent, or excipient.

Independent Claim 17:
This claim describes a method for treating type 2 diabetes mellitus. The method involves administering an effective amount of the compound described in Claim 1 to a patient who needs such treatment.

---

CAFC 2026 Dockets:

As of April 26, 2026, a search of CAFC 2026 dockets for US patent 9474780 did not return any specific results in the provided search snippets. However, it is noted that the patent family has ongoing litigation, including two PTAB cases (IPR2025-01024 and IPR2025-01346) filed in 2025, both of which were "Not Instituted - Procedural."